| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/28/2006 | US20060216285 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/28/2006 | US20060216284 free of a denaturing reagent and comprising of an antibody that binds to a respiratory syncytial virus (RSV) antigen, a human metapneumovirus (hMPV) antigen, integrin alpha v beta 3, CD2, CD19, an Eph receptor, or to IL-9 |
| 09/28/2006 | US20060216283 Inhibition of secretion from non-neuronal cells |
| 09/28/2006 | US20060216282 administering antibodies or fragments that binds to kit proteins (glycoprotein receptor protein-tyrosine kinase), to inhibit the kinase enzymatic reactions and to inhibit the stem cell factor signal transduction; treatment of skin disorders, asthma, inflammation, anaphylaxis, bronchospasm and tumors |
| 09/28/2006 | US20060216274 Induction of immune response to antigens expressed by recombinant adeno-associated virus |
| 09/28/2006 | US20060216237 Inhibition of angiogenesis and tumor development by IGFBP-4 |
| 09/28/2006 | US20060216236 Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development |
| 09/28/2006 | US20060216235 Monoclonal antibody or cellular cytotoxicity inducing ligand that competitively inhibits binding of isolated monoclonal antibody encoded by clone accession number PTA-5643 to its target antigen |
| 09/28/2006 | US20060216234 Cancerous disease modifying antibodies |
| 09/28/2006 | US20060216233 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 09/28/2006 | US20060216232 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 09/28/2006 | US20060216231 Methods for diagnosing and treating tumors and suppressing cd promoters |
| 09/28/2006 | DE19917195B4 Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor Peptide to induce an immune response against tumor cells containing this pharmzeutische compositions, uses thereof, nucleic acid coding therefor and these nucleic acid expression vector containing |
| 09/28/2006 | CA2814267A1 Sclerostin and the inhibition of wnt signaling and bone formation |
| 09/28/2006 | CA2603180A1 Influenza vaccine compositions and method for immunization against influenza disease |
| 09/28/2006 | CA2602956A1 Therapy of prostate cancer with ctla4 antibodies and hormonal therapy |
| 09/28/2006 | CA2602925A1 Methods for treating tumors and cancerous tissues |
| 09/28/2006 | CA2602456A1 Composition |
| 09/28/2006 | CA2602375A1 Antibodies against cd38 for treatment of multiple myeloma |
| 09/28/2006 | CA2602316A1 Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| 09/28/2006 | CA2602143A1 Fermentation process for the production of diphtheria toxin |
| 09/28/2006 | CA2602035A1 Framework-shuffling of antibodies |
| 09/28/2006 | CA2602028A1 Method for isolation of soluble polypeptides |
| 09/28/2006 | CA2601858A1 Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function |
| 09/28/2006 | CA2601706A1 Treatment of protein degradation disorders |
| 09/28/2006 | CA2601400A1 Improvements in or relating to treatment and prevention of viral infections |
| 09/28/2006 | CA2601394A1 Immunogens for vaccines against antigenically variable pathogens and diseases |
| 09/28/2006 | CA2601267A1 Novel anti-plgf antibody |
| 09/28/2006 | CA2601022A1 Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
| 09/27/2006 | EP1705487A2 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 09/27/2006 | EP1705191A2 Anti-interleukin-18 antibody |
| 09/27/2006 | EP1705186A1 Vaccine and antibody against Dictyocaulus viviparus |
| 09/27/2006 | EP1705185A2 Reagent for the diagnosis of rheumatoid arthritis |
| 09/27/2006 | EP1704869A1 VR-2332 viral nucleotide sequence and methods of use |
| 09/27/2006 | EP1704868A1 HLA binding peptides and their uses |
| 09/27/2006 | EP1704867A1 Cross-beta structures on microbial organisms |
| 09/27/2006 | EP1704167A1 A method to make a peptide-carrier conjugate with a high immunogenicity |
| 09/27/2006 | EP1704166A2 M-csf-specific monoclonal antibody and uses thereof |
| 09/27/2006 | EP1703917A2 Heh4 molecules and uses thereof |
| 09/27/2006 | EP1703914A1 Apicomplex vaccine strains of a family of sarcocystidae |
| 09/27/2006 | EP1703893A2 Novel anti-il 13 antibodies and uses thereof |
| 09/27/2006 | EP1703887A2 Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof |
| 09/27/2006 | EP1703806A1 Method for improving body weight uniformity and increasing carcass yield in animals |
| 09/27/2006 | EP1268759B1 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 09/27/2006 | EP1000162B1 $i(PSEUDOMONAS) EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE |
| 09/27/2006 | EP0951286B1 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations |
| 09/27/2006 | EP0770628B1 Reconstituted human antibody against human interleukin-8 |
| 09/27/2006 | CN1839201A Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| 09/27/2006 | CN1839157A Antibodies against interleukin-22 and uses therefor |
| 09/27/2006 | CN1839152A Modified i bordetella /i adenylate cyclase comprising or lacking cd11b/cd18 interaction domain and uses thereof |
| 09/27/2006 | CN1838968A Antibodies aimed to parathyroid hormone (PTH) and uses thereof |
| 09/27/2006 | CN1838967A Stabilized immunogenic HBc chimer particles |
| 09/27/2006 | CN1836729A Target antibody compound for killing tumour cell and its preparation method |
| 09/27/2006 | CN1276975C Recombinant protein containing C-terminal fragment of plasmodium MSP-1 |
| 09/27/2006 | CN1276778C SARS nucleic acid vaccine and preparation method |
| 09/27/2006 | CN1276777C SARS vaccine of adenovirus vector and preparation method, application of coronavirus S gene |
| 09/26/2006 | US7112666 Von Willebrand Factor (Vwf)-cleaving protease |
| 09/26/2006 | US7112664 Hepatitis B virus (HBV); cDNA encoding said variable region; vectors and transformed cells; use to develop monoclonal antibodies for immunotherapy or diagnosis; A transformant E. coli DH5 alpha /YRC-pCRA9Hv; |
| 09/26/2006 | US7112566 Treating narcolepsy or cataplexy in a mammal by administering hypocretin-1 to a peripheral tissue via injection, whereby the hypocretin-1 crosses the blood brain barrier of the mammal and preferably monitoring the patient's response |
| 09/26/2006 | US7112430 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 09/26/2006 | US7112427 Protein comprising mitogenic kinase activity for identifying modulators of inflammation, apoptosis and cell proliferation; antiproliferative agents |
| 09/26/2006 | US7112426 Human cAMP-dependent protein kinase beta-catalytic subunit |
| 09/26/2006 | US7112414 Masp-2, a complement-fixing enzyme, and uses for it |
| 09/26/2006 | US7112412 Binding to prostate specific membrane antigen (PSMA) with a radioactive monoclonal antibody or Fab fragments; detecting and kill the cancer cells; bioassay; radiotherapy |
| 09/26/2006 | US7112332 Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides |
| 09/26/2006 | US7112331 Vaccines against varicella zoster virus gene 63 product |
| 09/26/2006 | US7112330 diploid yeast strain; virus-like particle (VLP) comprising a first late 1 (L1) capsid protein from human papilloma virus (HPV) type 6 and a second L1 capsid protein from HPV type 16; Saccharomyces cerevisiae |
| 09/26/2006 | US7112329 useful in peptide-based immunotherapy for patients with spring tree pollinosis; diagnosis; |
| 09/26/2006 | US7112328 Composition for targeted cell treatment |
| 09/26/2006 | US7112327 Inhibition of complement activation |
| 09/26/2006 | US7112326 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/26/2006 | US7112325 Antibodies to calcium independent cytosolic phospholipase A2/B enzymes |
| 09/26/2006 | US7112324 CD 19×CD3 specific polypeptides and uses thereof |
| 09/26/2006 | US7112317 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker. |
| 09/26/2006 | CA2283464C Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 09/26/2006 | CA2102624C Transmission-blocking vaccine against malaria |
| 09/24/2006 | CA2516364A1 Method of modulation |
| 09/21/2006 | WO2006099592A2 Mannose immunogens for hiv-1 |
| 09/21/2006 | WO2006099574A2 Cockroach allergen gene expression and delivery systems and uses |
| 09/21/2006 | WO2006099561A1 Immunogenic compositions comprising lawsonia intracellularis |
| 09/21/2006 | WO2006099550A1 Methods of treating or preventing a disease, disorder or condition associated with a viral infection |
| 09/21/2006 | WO2006099481A2 Macromolecules comprising a thioether cross-link |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099175A2 Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer |
| 09/21/2006 | WO2006099101A1 Immunogenic compositions for mucosal delivery |
| 09/21/2006 | WO2006098987A2 Methods of inhibiting angiogenesis and tumor development |
| 09/21/2006 | WO2006098769A2 Multipathogen and monopathogen protection against the bacterial and viral infections associated with biological warfare, cardiac diseases, and cancers |
| 09/21/2006 | WO2006098758A2 Compositions, methods and kits relating to cthrc1, a novel modulator of collagen matrix |
| 09/21/2006 | WO2006098465A1 Prophylactic/therapeutic agent for cancer |
| 09/21/2006 | WO2006098304A1 Novel secretory protein derived from pituitary cell and use of the same |
| 09/21/2006 | WO2006097914A2 Compositions of hsp60 peptides and viral antigens for vaccination and diagnosis |
| 09/21/2006 | WO2006097851A2 Combination vaccines with whole cell pertussis antigen |
| 09/21/2006 | WO2006097689A2 Antibodies against candida antigens |
| 09/21/2006 | WO2006097642A2 Composition comprising the n-terminal region of leishmania histone h2b, use thereof for inducing an immune response |
| 09/21/2006 | WO2006097530A2 Cat allergen fusion proteins and uses thereof |
| 09/21/2006 | WO2006097120A1 A process for the preparation of hypoallergenic alimentary proteins |
| 09/21/2006 | WO2006096970A1 Synthetic anti-candida albicans oligosaccharide based vaccines |
| 09/21/2006 | WO2006083286A9 Genetically engineered swine influenza virus and uses thereof |
| 09/21/2006 | WO2006058300A3 Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 09/21/2006 | WO2006050237A3 Method and compositions for determining resistance of susceptibility of hiv-1 to stavudine |